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Recurrent HCV infection following liver transplantation
can lead to accelerated allograft injury that is difficult to
treatwith interferon. The aimof this study is to describe
the first ever useof an interferon-free, all oral regimen in
a liver transplant recipientwith severe recurrent HCV. A
54-year-old male with HCV genotype 1b developed
severe cholestatic HCV at 6 months posttransplant
with ascites, AST 503 IU/mL, alkaline phosphatase of
298 IU/mL, HCV RNA of 12 000 000 IU/mL, and histo-
logical cholestasiswith pericellular fibrosis. Sofosbuvir,
an HCV polymerase inhibitor (400 mg/day), and dacla-
tasvir, an HCV NS5A replication complex inhibitor
(60 mg/day),wereco-administeredfor24weeks.Within
4 weeks of initiating treatment, serum HCV RNA levels
became undetectable and liver biochemistries normal-
izedwith concomitant resolution of ascites. The patient
achieved a sustained virological response with un-
detectableHCVRNAat9monthsposttreatment.During
and following treatment, the daily dose and blood level
of tacrolimusremainedstableandunchanged.Therapid
andsustainedsuppressionofHCVreplicationinthisliver
transplantrecipientprovidesgreatpromisefortheuseof
combination oral antiviral regimens in other immuno-
suppressed and interferon refractory HCV patients.
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Introduction
Hepatitis C virus (HCV) infection is the leading indication for
liver transplantation (LT) in the United States and many
parts of the world (1). However, patient survival is
significantly lower in HCV patients compared to other
recipients due, in part, to the inevitable recurrence of HCV
infection in the allograft that is characterized by high levels
of HCV replication that can lead to accelerated necroin-
flammation and fibrosis (2,3). Peginterferon and ribavirin
combination therapy has been used in selected LT
recipients with moderate to severe recurrent HCV but is
limited by frequent side effects and low antiviral effica-
cy (4,5). Although the protease inhibitors, boceprevir and
telaprevir, markedly improve response rates when com-
bined with peginterferon and ribavirin in HCV genotype 1
patients, both of these drugs are substrates and inhibitors
of CYP3A4 which can lead to potentially severe drug–drug
interactions when co-administered with calcineurin inhib-
itors (6,7). Preliminary data indicate that these drugs are
associated with a high rate of anemia, infection and poor
tolerability in LT recipients (8,9). As a result, use of these
agents with peginterferon and ribavirin is currently not
recommended in LT recipients until further studies have
been completed. Daclatasvir (DCV) is a potent NS5A
replication complex inhibitor with demonstrated antiviral
activity in HCV genotype 1 patients when co-administered
with peginterferon and ribavirin (10,11). Similarly, sofosbu-
vir (GS-7977), a potent oral nucleotide analogue inhibitor of
HCV polymerase activity, has shown great promise when
combined with ribavirin with or without peginterferon in
both na€lve and previously treated patients with multiple
HCV genotypes (12,13). Both of these investigational
agents are orally dosed once a day and have had a generally
favorable side effect profile. In addition, neither drug is
anticipated to cause significant drug–drug interactions
when co-administered with other CYP3A4 sub-
strates (14,15). The aim of this study is to report the
first ever use of sofosbuvir combined with daclatasvir in a
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LT recipient with severe recurrent cholestatic HCV
infection.
Results
A 54-year-old African American male with diabetes and
coronary artery diseasedeveloped liver failure due to severe
HCV genotype 1b infection that was resistant to prior
interferon monotherapy and peginterferon and ribavirin
combination therapy given pretransplant. At the time of LT,
hehadrefractoryasciteswitha laboratoryMELDscoreof24.
Within 6 months of LT, he developed severe recurrent
cholestatic HCV infection with an HCV RNA level of
12 000 000 IU/mL, a serum aspartate aminotransferase
(AST)of 503 IU/L, alanineaminotransferase (ALT)of 584 IU/
L, alkaline phosphataseof 298 IU/L, total bilirubin of 1.9 mg/
dL (direct 1.5 mg/dL) and INR of 1.3. He was fatigued with
moderate ascites on exam and his body mass index was
22.2 kg/m2. An ERCP at month 4 postLT showed no
evidenceof a biliary stricture, a liver ultrasoundwithDoppler
excluded portal vein thrombosis, and an inferior venacava-
gram with pressure measurements at month 6 postLT
showed no evidence of venous outflow obstruction. A liver
biopsy demonstrated mildly active chronic hepatitis C with
focal bridging fibrosis and diffuse swelling of hepatocytes
with perisinusoidal collagen deposition, both common
features of fibrosing cholestatic hepatitis (16) (Figure 1).
Despite early discontinuation ofmycophenolatemofetil and
minimizing his tacrolimus and prednisone, his clinical status
continued to deteriorate. Following the approval of an
emergency IND by the FDA (#113 500), the patient signed a
written informed consent approved by the local IRB to
receive DCV, 60 mg/day (Bristol-Meyers Squibb, Princeton,
NJ) and sofosbuvir 400 mg/day (Gilead Sciences, Foster
City, CA) for 24 weeks at the University of Michigan
Institute for Clinical and Health research Unit (Ann Arbor,
MI). The research protocol included a pretreatment
baseline visit as well as planned study visits at weeks 1,
2, 3, 4 and every 2 weeks through week 24 as well as at
posttreatment weeks 4 and 24 wherein routine labs and
tacrolimus levels were obtained as well as monitoring for
adverse events. Study medications were dispensed on a
monthly basis and the patient kept a log of daily medication
administration as well as all concomitant medications.
Serum HCV RNA was measured using the Roche Cobas
Taqman assay (lower limit of quantification ¼ 43 IU/mL) at
weeks 0, 1, 2, 4, 12 and 24 and months 1, 2 and 6
posttreatment.
On the first day of drug dosing, his serum creatinine was
1.0 mg/dL, hemoglobin 13.9 g/dL, white blood cell count
(WBC) 4.4  103/mL and platelets were 166  103/mL.
Concomitant medications included furosemide, pantopra-
zole, vitamin D, tacrolimus 1.5 mg twice a day, insulin NPH
32 units each AM and prednisone 3 mg/day. The patient
was IL28-B genotype CT. Within 4 weeks of starting
treatment, HCVRNAwas below the lower limit of detection
(i.e. <43 IU/mL) and his liver biochemistries normalized
(AST 24, ALT 17, alkaline phosphatase 96, total bilirubin 0.8)
along with improvement of his albumin to 4.3 g/dL and INR
of 1.0 (Figure 2). In addition, his symptoms of fatigue and
ascites resolved.
The patient completed 24 weeks of sofosbuvir and
daclatasvir combination therapywith persistently undetect-
able HCV RNA and normal liver biochemistries. The patient
did not experience any adverse laboratory or clinical
adverse events attributed to either study drug. In fact
with improvement in his fatigue, he was able to return to
work by month 3 of antiviral treatment. At the end of
treatment, his hemoglobin was 15.0 g/dL, WBC 7.7  103/
mL, platelets 202  103/mL, INR 1.0 and creatinine was
1.3 mg/dL. The tacrolimus dose remained unchanged
throughout antiviral treatment with a stable serum trough
Figure 1: A: The hepatocytes are swollen with pale cytoplasm and arranged in clusters rather than cords, a common finding in
fibrosing cholestatic HCV. The only evidence of inflammation is the few sinusoidal lymphocytes (hematoxylin and eosin 400). B: Fine
blue collagen fibers separate the clusters of pale swollen hepatocytes (trichrome stain, 200).
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level of 4–6 ng/mL. During posttreatment follow-up, the
patient did not receive any additional antiviral agent andwas
maintained on tacrolimus. He has remained well with
undetectable HCV RNA at 9 months follow-up consistent
with a sustained virological response. In addition, his serum
AST 13 IU/mL, ALT 18 IU/mL, alk phos 101 IU/mL and total
bilirubin of 0.5 mg/dL remain normal. Finally, his serum
creatinine is stable at 1.3 mg/dL, hemoglobin 15.4 g/dL,
WBC 7.8  103/mL and platelets of 195  103/mL.
Daclatasvir Pharmacokinetics
Daclatasvir pharmacokinetic parameters were stable
throughout dosing (Table 1). The daclatasvir trough concen-
trations ranged from 57 to 196 ng/mL which is within the
range of exposure where DCV has demonstrated antiviral
activity when co-administered alone or in combination with
peginterferon and ribavirin or other direct acting antiviral
agents. TheDCVTmax for this subjectwas 4 hwith a Cmax of
597 ng/mL which are also within the anticipated range of
exposure.
Discussion
Severe recurrent HCV infection following LT is very
challenging to manage. Interferon and ribavirin are difficult
to initiate in many LT recipients due to their persistent
pancytopenia from residual portal hypertension/spleno-
megaly and chronic renal insufficiency that precludes use
of full dose peginterferon and ribavirin, respectively (4). In
addition, as many as 30–70% of treated patients require a
medication dose reduction and 20–40% terminate therapy
prematurely due to intolerable side effects. Furthermore,
there is increasing recognition of immune-mediated allo-
graft dysfunction due to Interferon thatmay not only require
early discontinuation of treatment but also lead to prema-
ture graft failure and/or even death (5,17). However, since
recent studies have demonstrated that LT recipients who
achieve SVR have a significantly improved survival com-
pared to nonresponders and untreated patients, there is an
urgent need to develop safer and more effective therapies
for LT recipients (18,19).
The current study demonstrates that sofosbuvir in combi-
nation with daclatasvir is an efficacious and well-tolerated
interferon free regimen in a LT recipient with severe
recurrent cholestatic HCV infection. Ongoing studies have
demonstrated that each of these agents when combined
Figure 2: Serum HCV RNA was 12 000 000 IU/mL, ALT 218 IU/L and alkaline phosphatase 236 IU/L prior to treatment. Within
2 weeks of initiating combination therapy, the serum ALT and alkaline phosphatase levels had normalized while serum HCV RNA became
undetectable (<43 IU/mL) at week 4 and remained so during and after treatment. The patient has remained HCV RNA negativewith normal
liver biochemistries at 9 months of follow-up consistent with a sustained virological response.
Table 1: Daclatasvir Pharmacokinetic parameters during 24weeks
of treatment with sofosbuvir
Week 2 pK data
(time in hours)
Daclatasvir concentration
(ng/mL)
0 57
0.5 h 46
1.0 h 48
2.0 h 215
4.0 h 597
6.0 h 400
Study week AM trough concentration (ng/mL)
6 76
8 91
12 149
24 196
Sofosbuvir and Daclatasvir After Liver Transplantation
1603American Journal of Transplantation 2013; 13: 1601–1605
with peginterferon and ribavirin markedly improves SVR
rates compared to peginterferon and ribavirin alone in HCV
genotype 1 patients (11,13). In addition, potent antiviral
efficacy of sofosbuvir combined with DCV with or without
ribavirin for 24 weeks has been demonstrated in HCV
genotype 1 patients (20). In those phase 2 studies, 100%of
patients became HCV RNA negative at week 4 and there
was no evidence of resistance to either agent during or after
therapy. Consistent with these findings, our interferon
refractory patient who had a very high baseline HCV RNA
level in the setting of tacrolimus and prednisone immuno-
suppression, achieved a serum HCV RNA below the lower
limit of detection at week 4 and remained undetectable
during and after treatment. These data demonstrate the
potent antiviral activity of these individual agents when co-
administered even to an immunosuppressed LT recipient.
Furthermore, the excellent safety and side effect profile of
this drug combination makes this interferon free regimen
an attractive treatment option for other LT recipients with
recurrent HCV infection. Daclatasvir in combination with
peginterferon and ribavirin has generally been well-tolerat-
ed in over 1100 patients treated worldwide. No significant
increase in the rate of laboratory or clinical adverse events
was observed when compared to peginterferon and
ribavirin alone and no unique daclatasvir related adverse
events were identified (21). Sofosbuvir has also been
generally well tolerated with use in over 500 patients
worldwide and an adverse event profile similar to placebo
when given with ribavirin alone or in combination with
peginterferon and ribavirin (22). However, the dose and/or
dosing interval of sofosbuvir may need to be altered in
patients with severe renal impairment (i.e. GFR < 30 mL/
min) as renal elimination is the main route of clearance for
sofosbuvir and its metabolites (23). In ongoing studies,
some patients receiving sofosbuvir have reported head-
ache and insomnia which are difficult to attribute to the
sofosbuvir versus the peginterferon and ribavirin. Although
preliminary data demonstrate that boceprevir or telaprevir
with peginterferon and ribavirin can lead to rapid suppres-
sion of HCV replication in LT recipients with genotype 1,
significant side-effects including transfusion dependent
anemia, renal insufficiency, infection and even death have
been reported highlighting the need for simpler and better
tolerated therapies (8,9).
The lack of clinically apparent drug–drug interactions with
the calcineurin inhibitors make both daclatasvir and
sofosbuvir very attractive for future use in LT recipients
with recurrent HCV infection (14,15). Of note, another LT
recipient with severe recurrent HCV infection was recently
treated with DCV, peginterferon and ribavirin for 24 weeks
and did not experience any apparent drug–drug interactions
with cyclosporine (24). In conclusion, the current study
demonstrates the feasibility of combining potent oral
antiviral agents with differing mechanisms of action in an
LT recipient with severe recurrent cholestatic HCV infec-
tion. Although this African American patient had an
unfavorable IL28-B genotype and a lack of response to
prior peginterferon and ribavirin therapy, he rapidly re-
sponded to this interferon-free regimen. This case illus-
trates that the use of potent oral antiviral agents such as
daclatasvir and sofosbuvir even early after transplantation
offers great promise to the many HCV patients worldwide
who are experiencing reduced quality of life and survival
due to recurrent infection (2,18). Based upon this case,
prospective studies involving these and other investiga-
tional oral antiviral agents in development should be
undertaken for the growing number of LT recipients with
clinically significant recurrent HCV infection. In addition, use
of interferon-free regimens is of great interest in LT
candidates with decompensated cirrhosis to reduce the
frequency and severity of HCV recurrence but further
studies in this difficult to treat population are needed.
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